AR and prostate carcinoma: Metastatic prostate cancer can be present either at the time of diagnosis, termed hormone-sensitive (mHSPC), or following therapeutic resistance to androgen/androgen receptor (AR) pathway inhibitors, known as metastatic castration-resistant prostate cancer (mCRPC) [3].